179523-60-5

Basic information

• Product Name: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid
• Synonyms: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid
• CAS NO: 179523-60-5
• Molecular Weight: 336.368
• Mol File: 179523-60-5.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(179523-60-5)
• EPA Substance Registry System: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(179523-60-5)

Safety Data

• Hazardous Substances Data: 179523-60-5(Hazardous Substances Data)

Usage

Molecular structure

2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid is a chemical compound with a specific molecular structure that includes a pyridine ring, a sulfonamide group, and an acetic acid group.

Derivative of pyridine

This compound is a derivative of pyridine, which is a heterocyclic aromatic compound that is commonly found in many pharmaceuticals.

Contains a sulfonamide group

The presence of a sulfonamide group in this compound suggests that it may have potential pharmaceutical applications, as sulfonamides are commonly used in medications for their antibacterial properties.

Biological activity

The compound may have biological activity due to its interaction with enzymes or receptors in the body, which could make it a potential drug candidate for treating various medical conditions.

Need for further research

Further research is needed to fully understand the properties and potential uses of this compound in the field of medicine, including its safety, efficacy, and mechanism of action.

Upstream product

• 1939-99-7 benzenesulfonyl chloride 
• 76-05-1 trifluoroacetic acid 
• 179524-35-7 t-butyl (3-benzylsufonylamino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 147269-61-2 (2-hydroxy-6-methylpyridin-3-yl)carbamic acid benzyl ester 
• 147269-61-2 benzyl N-(6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)carbamate 
• 38116-61-9 2-hydroxy-6-methylnicotinic acid 
• 179524-31-3 t-butyl [(t-butyl 3-carboxyacetate)-6-methyl-2-oxo-1,2-dihydro-1-pyridyl]acetate 
• 179524-32-4 t-Butyl (3-Carboxy-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 179524-33-5 2-[6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2H-pyridin-1-yl]acetic acid t-butyl ester 
• 38116-61-9 6-Methylpyrid-2-one-3-carboxylic Acid 
• 179524-34-6 t-Butyl (3-Amino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 

Downstream Products

• 193278-22-7 [3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1,2-dihydropyridyl]acetyl-Ng-nitro-L-argininal ethyl cyclol 

Relevant articles and documents

Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.

Optimization of lead compounds 1 and 2 resulted in novel, selective, and potent thrombin inhibitors incorporating weakly basic heterobicyclic P(1)-arginine mimetics. The design, synthesis, and biological activity of racemic thrombin inhibitors 17-29 and enantiomerically pure thrombin inhibitors 30-33 are described. The arginine side-chain mimetics used in this study are 4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine, 4,5,6,7-tetrahydro-2H-indazole, and 2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-ylamine.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.

Aromatic heterocyclic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.